Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

InforSense Partners with U.K.’s Leading Institutions to Combat Alzheimer’s Disease

Published: Wednesday, December 03, 2008
Last Updated: Wednesday, December 03, 2008
Bookmark and Share
Translational research solution to help accelerate early diagnosis and personalized medicine treatments.

InforSense Ltd. has announced that the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at the South London and Maudsley National Health Service (NHS) Foundation Trust (SLaM) and Institute of Psychiatry, King’s College London will use InforSense’s translational research solutions in Alzheimer’s disease studies to advance the development of early diagnostic tools and develop personalized medicine treatments within mental health research.

For the first time, informaticians, researchers and clinicians will be able to directly access their entire patient and ‘omics’ data  through a common data analysis platform. The InforSense solution will eliminate errors associated with manual data processes and bottlenecks relating to data access and analysis by non specialist end users.

“Our research centers on understanding the molecular and cellular events that take place in the brain in Alzheimer’s disease and in particular we are working on blood based biomarkers to aid early diagnosis,” said Simon Lovestone, Professor of Old Age Psychiatry at King’s College London and Director of the Biomedical Research Centre for Mental Health.

“The translational solutions that InforSense provides will enable us to have an integrated data set under a common system that informaticians, researchers and clinicians can all use to access and analyze data. This will result in improved data sharing and removal of access bottlenecks, speeding up the speed and accuracy of novel biomarker identification.”

Translational research is the practice of linking clinical and research data to identify early diagnostics, also known as biomarkers, improve disease understanding and ultimately enhance patient care.

The InforSense Translational Research solution, including the InforSense platform, ClinicalSense, GenSense, and BioSense, will be used by the Biomedical Research Centre for Mental Health to integrate and analyze patient, genotyping, transcriptomics, proteomics and MRI data to support the identification of biomarkers. Researchers will also be able to access and analyze data using the VisualSense interactive web portal.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InforSense GenSense Achieves GeneChip-compatible™ Status with the Affymetrix GeneChip® Microarray Platform
Affymetrix has become a member of InforSense’s Open Workflow Partner Network joining over 40 other partners in the program.
Tuesday, August 07, 2007
InforSense® Announces Conference Series
The InforSense Users Conference will provide opportunity to learn how InforSense KDE is being used to facilitate business-critical decision-making across a variety of industries.
Tuesday, November 14, 2006
$10 Million Investment to Boost InforSense Expansion
Fleming Family & Partners Private Equity and Imperial Innovations lead strategic investment round.
Tuesday, October 10, 2006
EU-Funded ARGUGRID Project Adopts InforSense® Integrative Analytics Technology
InforSense to provide integrative analytics environment to support collaborative decision making.
Wednesday, October 04, 2006
InforSense® Appoints David Hadfield as Chief Operating Officer
Former Spotfire executive strengthens InforSense management team.
Tuesday, October 03, 2006
Bayer Selects InforSense for Next Generation Integrative Analytics Infrastructure
InforSense KDE, will provide Bayer with a flexible rapid application development platform to optimize their drug discovery decision-making.
Friday, September 16, 2005
Scientific News
Health Risks of Saturated Fats Aggravated by Immune Response
Research shows that the presence of saturated fats resulted in monocytes migrating into the tissues of vital organs.
Changing the Biological Data Visualisation World
Scientists at TGAC, alongside European partners, have created a cutting-edge, open source community for the life sciences.
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!